
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp demonstrated a solid third quarter in 2025, reporting revenue of $21.5 million, which marks a 5% year-over-year increase largely attributed to the continued adoption of the Zephyr Valve for severe emphysema treatment. The company's ability to maintain a gross margin of 75% while narrowing its net loss to $14 million highlights its commitment to operational efficiency, and its gross profit rose to $16.1 million from $15.0 million the previous year. Additionally, the company's international revenue saw a significant 15% increase, indicating robust expansion efforts that, along with disciplined investment strategies and the introduction of new leadership, position Pulmonx for future growth and sustained market presence.
Bears say
Pulmonx Corp reported preliminary Q3 revenue of approximately $21.5 million, indicating a sequential decline compared to Q2’s revenue of $23.9 million, which reflects a weaker growth trajectory and led to a reduction in full-year guidance to $90 million–$92 million. The company faced challenges with execution risk amid changes in management, as it transitioned back to former CEO Glen French and appointed Derrick Sung as COO/CFO. Additionally, pressures on both top-line growth and gross margins, which decreased from 72% in Q2, further contribute to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares